Primary |
Product Used For Unknown Indication |
36.6% |
Plasma Cell Myeloma |
32.0% |
Prophylaxis |
8.7% |
Thrombosis Prophylaxis |
7.2% |
Pain |
2.7% |
Infection Prophylaxis |
2.0% |
Constipation |
1.4% |
Hypertension |
1.2% |
Nausea |
1.0% |
Supplementation Therapy |
1.0% |
Back Pain |
0.8% |
Myelofibrosis |
0.8% |
Anxiety |
0.7% |
Anaemia |
0.7% |
Amyloidosis |
0.6% |
Depression |
0.6% |
Multiple Myeloma |
0.6% |
Insomnia |
0.6% |
Neutropenia |
0.6% |
Analgesic Therapy |
0.4% |
|
Plasma Cell Myeloma |
34.3% |
Death |
10.2% |
Thrombocytopenia |
9.7% |
Pneumonia |
6.5% |
Septic Shock |
6.0% |
Pancytopenia |
4.6% |
Pyrexia |
3.2% |
Renal Failure |
3.2% |
Renal Failure Acute |
3.2% |
Sepsis |
2.8% |
Syncope |
2.3% |
White Blood Cell Count Decreased |
2.3% |
Disease Progression |
1.9% |
Febrile Neutropenia |
1.9% |
Platelet Count Decreased |
1.9% |
Lung Infection |
1.4% |
Unevaluable Event |
1.4% |
Upper Respiratory Tract Infection |
1.4% |
Cellulitis |
0.9% |
Chronic Obstructive Pulmonary Disease |
0.9% |
|
Secondary |
Product Used For Unknown Indication |
42.0% |
Plasma Cell Myeloma |
19.3% |
Prophylaxis |
10.7% |
Thrombosis Prophylaxis |
4.9% |
Multiple Myeloma |
4.6% |
Pain |
4.1% |
Infection Prophylaxis |
1.7% |
Constipation |
1.7% |
Hypertension |
1.3% |
Insomnia |
1.3% |
Anxiety |
1.2% |
Supplementation Therapy |
1.0% |
Sleep Disorder |
0.9% |
Anticoagulant Therapy |
0.8% |
Back Pain |
0.8% |
Depression |
0.8% |
Myelofibrosis |
0.8% |
Nausea |
0.8% |
Nasopharyngitis |
0.7% |
Upper Respiratory Tract Infection |
0.7% |
|
Plasma Cell Myeloma |
12.1% |
Pyrexia |
9.6% |
Thrombocytopenia |
9.6% |
Colon Cancer |
7.6% |
Pneumonia |
7.6% |
Pancytopenia |
7.0% |
Liver Injury |
6.4% |
Renal Failure |
5.7% |
Syncope |
5.1% |
White Blood Cell Count Decreased |
3.8% |
Lung Infection |
3.2% |
Sepsis |
3.2% |
Urticaria |
3.2% |
Invasive Ductal Breast Carcinoma |
2.5% |
Platelet Count Decreased |
2.5% |
Pulmonary Embolism |
2.5% |
Septic Shock |
2.5% |
Fatigue |
1.9% |
Febrile Neutropenia |
1.9% |
Interstitial Lung Disease |
1.9% |
|
Concomitant |
Product Used For Unknown Indication |
65.4% |
Insomnia |
7.7% |
Multiple Myeloma |
7.7% |
Nausea |
7.7% |
Agitation |
3.8% |
Anxiety |
3.8% |
Vomiting |
3.8% |
|
|